Is BioXcel Therapeutics, Inc. (BTAI) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 318.1% / 30% | 92.2% / 30% | 0.4% / 30% | 114.83% / 5% | ✗ NOT HALAL |
| DJIM | 318.1% / 33% | 92.2% / 33% | 0.4% / 33% | 114.83% / 5% | ✗ NOT HALAL |
| MSCI | 268.5% / 33% | 77.9% / 33% | 0.3% / 33% | 114.83% / 5% | ✗ NOT HALAL |
| S&P | 318.1% / 33% | 92.2% / 33% | 0.4% / 33% | 114.83% / 5% | ✗ NOT HALAL |
| FTSE | 268.5% / 33% | 77.9% / 33% | 0.3% / 50% | 114.83% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -28.2% | |
| Operating Margin | -14320.4% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -67.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$72M |
| Free Cash Flow | -$72M |
| Total Debt | $103M |
| Current Ratio | 1.2 |
| Total Assets | $38M |
Price & Trading
| Last Close | $1.37 |
| 50-Day MA | $1.61 |
| 200-Day MA | $2.27 |
| Avg Volume | 1.4M |
| Beta | 0.2 |
|
52-Week Range
$1.17
| |
About BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is BioXcel Therapeutics, Inc. (BTAI) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), BioXcel Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is BioXcel Therapeutics, Inc.'s debt ratio?
BioXcel Therapeutics, Inc.'s debt ratio is 318.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 268.5%.
What are BioXcel Therapeutics, Inc.'s key financial metrics?
BioXcel Therapeutics, Inc. has a market capitalization of $31M, and revenue of $2M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.